Fenwick & West represented Pionyr Immunotherapeutics, Inc., a leading company in the development of antibody therapeutics, in the intellectual property due diligence aspect of its $62 million Series B financing. New Enterprise Associates led the round, with participation from Sofinnova Ventures and Vida, along with existing investors, OrbiMed, SV Health Investors, Osage University Partners and Mission Bay Ventures.
The funding will be used to advance the research and development of antibody-based therapeutics targeting the tumor microenvironment. More information about Pionyr’s $62 million Series B financing can be obtained from the company press release.
The Fenwick transaction team was led by intellectual property attorneys Michael Shuster and Kevin Kabler.